NEJM Evidence Impact Factor in 2026: Does It Have a JIF Yet?
Research Scientist, Neuroscience & Cell Biology
Works across neuroscience and cell biology, with direct expertise in preparing manuscripts for PNAS, Nature Neuroscience, Neuron, eLife, and Nature Communications.
Targeting NEJM?
See scope, acceptance rate, submission tips, and what editors actually want.
NEJM Evidence doesn't currently have a Journal Impact Factor in JCR. That's not a flaw — it's a timing issue. The journal launched in January 2022, and JCR requires two full years of citation data before calculating a JIF. The first JIF is expected in the 2025 or 2026 JCR release.
The absence of a JIF doesn't reflect the journal's quality or reach. NEJM Evidence is published by the NEJM Group, edited by senior editors with NEJM pedigree, and covers high-quality clinical trials and evidence synthesis at the same standards as its parent journal.
What Is NEJM Evidence?
NEJM Evidence is a digital-first clinical journal focused on clinical trials, systematic reviews, and original research in evidence-based medicine. It was launched to address a gap: the original NEJM's limited space relative to the volume of high-quality clinical research being produced.
Key characteristics:
- Publisher: Massachusetts Medical Society (same as NEJM)
- Editor-in-Chief: Harlan Krumholz, MD (Yale) and other senior editors
- Launch date: January 2022
- Format: Digital-only, open access option available
- Scope: Clinical trials, systematic reviews, clinical epidemiology, health services research
Why No JIF Yet (and What That Means)
The Journal Impact Factor is calculated from citations received in years 1 and 2 after publication. Because NEJM Evidence only launched in 2022, the first complete two-year citation window needed for JCR 2024 is still accumulating. The journal will almost certainly receive a JIF in the next JCR cycle.
For authors, this creates a practical consideration:
Some promotion committees and grant applications specifically require a listed JIF. If your institution uses JIF as a formal filter for promotion cases, submitting to NEJM Evidence carries a risk — reviewers may not count it the same way they'd count a NEJM publication, at least not yet.
If your institution is more flexible about journal quality vs. listed metrics, NEJM Evidence's pedigree and editorial standards should carry weight equivalent to other high-quality clinical journals.
NEJM Evidence vs NEJM vs BMJ
Journal | IF | Best for |
|---|---|---|
NEJM | 78.5 | Practice-changing clinical trials, landmark studies |
NEJM Evidence | No JIF yet | High-quality clinical trials, evidence synthesis |
BMJ | 42.7 | Clinical research, health policy, global medicine |
JAMA | 55.0 | Broad clinical medicine, trials, US policy relevance |
Lancet | 88.5 | Global health, major international trials |
Annals of Internal Medicine | ~21 | Internal medicine, clinical guidelines |
NEJM Evidence sits between NEJM (harder to get into, bigger splash) and mid-tier clinical journals. It's a strong option for rigorous clinical work that might not clear NEJM's threshold but deserves the NEJM Group's reach and audience.
Who Should Submit to NEJM Evidence
Good fit:
- Randomized clinical trials with definitive or substantial findings in clinical medicine
- Large systematic reviews or meta-analyses with clear practice implications
- Clinical epidemiology studies with real-world relevance to medical decision-making
- Secondary analyses of major trials that produce practice-relevant insights
Not a good fit:
- Basic science or mechanistic laboratory work
- Small observational studies without meaningful clinical sample sizes
- Case reports or case series
- Narrow disease-specific work better suited to specialist journals
The JIF Question in Context
Impact factor is a lagging indicator — it measures citation history, not current quality. NEJM Evidence is new, its editorial standards are high, and its parentage is strong. The JIF will come.
If you're choosing between NEJM Evidence and a journal that has a JIF but lower editorial standards, the JIF alone isn't a good reason to choose the lower-quality venue. Talk to your department chair or mentors about how your institution actually weighs journal prestige vs. listed metrics.
Submission Tips
- Structure your trial properly. CONSORT compliance, pre-registered protocol, and pre-specified endpoints are expected
- Clinical relevance is the filter. State the practice implication in the cover letter clearly
- NEJM Evidence has faster turnaround than NEJM. This can be a practical advantage for time-sensitive findings
- Open access option is available if your funder requires it
More Resources
Free scan in about 60 seconds.
Run a free readiness scan before you submit.
More Articles
Want the full picture on NEJM?
Anthropic Privacy Partner - zero retention